OBJECTIVE: The objective of this article is to assess the effects of sumatriptan 
monotherapy, telcagepant monotherapy, and their combination on blood pressure 
(BP) in migraine patients during a headache-free period.
METHODS: A double-blind, placebo-controlled, four-period, single-dose, 
randomized crossover study in 24 migraine patients was conducted. In each 
period, patients received a single oral dose of sumatriptan 100 mg alone, 
telcagepant 600 mg alone, sumatriptan 100 mg coadministered with telcagepant 600 
mg, or placebo. Semi-recumbent BP was measured pre-dose and at seven post-dose 
time points over a period of six hours. Individual time-weighted averages in 
mean arterial pressure (MAP) were evaluated using a linear mixed-effects model. 
The pharmacokinetics of sumatriptan alone and in the presence of telcagepant 
were also evaluated using limited sampling times.
RESULTS: The mean difference in time-weighted (0-2.5 h) MAP (90% confidence 
interval) was 1.2 mmHg (-0.2, 2.7) between telcagepant and placebo, 4.0 mmHg 
(2.5, 5.5) between sumatriptan and placebo, and 1.5 mmHg (0.0, 3.0) between 
telcagepant with sumatriptan vs sumatriptan alone. When coadministered with 
telcagepant, the AUC0-6h and C(max) of sumatriptan were increased by 23% and 
24%, respectively. The small MAP increases observed after coadministration could 
possibly be associated with the slight elevations in sumatriptan levels.
CONCLUSION: Telcagepant does not elevate mean MAP, and coadministration of 
telcagepant with sumatriptan results in elevations in MAP similar to those 
observed following administration of sumatriptan alone in migraineurs during the 
interictal period. When coadministered, telcagepant slightly increases the 
plasma levels of sumatriptan, but without an apparent clinically meaningful 
effect.